Advanced NMR of Wilmington, MA, and Medical Diagnostics of Burlington,MA, are ready to send their merger proposal to a shareholder voteafter the Securities and Exchange Commission declared effectivea registration statement containing the proposal. The
Advanced NMR of Wilmington, MA, and Medical Diagnostics of Burlington,MA, are ready to send their merger proposal to a shareholder voteafter the Securities and Exchange Commission declared effectivea registration statement containing the proposal. The companiesannounced the merger in May after a protracted battle betweenMDI and erstwhile suitor Raytel (SCAN 5/10/95). The shareholdervotes are scheduled for Aug. 31.
Advanced NMR also reported financial results last week thatshow revenues of $4.3 million for the second quarter (end-June),up 195% compared to $1.5 million in sales in the same period lastyear. Net income for the quarter was $393,000 compared to a netloss of $593,000 in the second quarter of 1995.
The company said the improving results were due to growingsales of its InstaScan echo-planar imaging package, as well asthe shipment of two 3-tesla MRI scanners.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.